Document is current
Any future updates will be listed below
-
Authors
Puertas, Borja
González-Calle, Verónica
Sobejano-Fuertes, Eduardo
Escalante, Fernando
Rey-Bua, Beatriz
Padilla, Irene
García-Sanz, Ramón https://orcid.org/0000-0003-4120-2787
Puig, Noemi
Gutiérrez, Norma C.
Mateos, María-Victoria https://orcid.org/0000-0003-2390-1218
- License Information
-
More Information
Article History
Received: 5 December 2022
Revised: 23 February 2023
Accepted: 27 February 2023
First Online: 20 March 2023
Competing interests
: BP has received honoraria from Janssen and Aptitude Health. VG-C has received honoraria from Janssen and Celgene, research funding from Janssen, and has benefited from consulting and advisory roles with Prothena and Janssen. ES-F has received speaker’s fees from Amgen and Janssen and consultancy fees from Janssen. FE has received speaker’s fees from Janssen, Sanofi, Amgen and Sanofi, and honoraria from consulting and advisory roles from Janssen, Biogene, Sanofi, GSK, Takeda, Amgen and BMS. IP has received speaker’s fees from Sanofi, Alexion, Kyowa, and Kirin. BR-B has received speaker’s fees from Janssen. RG-S has received honoraria from Janssen, Takeda, and Amgen, and research funding from Gilead Sciences and Incyte. NP has received honoraria for consulting and advisory roles with Amgen, Celgene, Janssen, Takeda, The Binding Site, GSK, and Sanofi. NCG has received honoraria from Janssen and Amgen. M-VM has received honoraria from lectures and membership of advisory boards from Janssen, BMS-Celgene, Amgen, Takeda, Abbvie, Sanofi, Oncopeptides, Adaptive, Roche, Pfizer, Regeneron, GSK, Bluebird Bio, and Sea-Gen.
